Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 20 entries
Sorted by: Best Match Show Resources per page
The familial aspect of malignant melanoma.

Archives of dermatology

MILLER TR, PACK GT.
PMID: 14474110
Arch Dermatol. 1962 Jul;86:35-9. doi: 10.1001/archderm.1962.01590070041005.

No abstract available.

Cite
MILLER TR, PACK GT. The familial aspect of malignant melanoma. Arch Dermatol. 1962;86:35-9doi: 10.1001/archderm.1962.01590070041005.
MILLER, T. R., & PACK, G. T. (1962). The familial aspect of malignant melanoma. Archives of dermatology, 8635-9. https://doi.org/10.1001/archderm.1962.01590070041005
MILLER, T R, and PACK, G T. "The familial aspect of malignant melanoma." Archives of dermatology vol. 86 (1962): 35-9. doi: https://doi.org/10.1001/archderm.1962.01590070041005
MILLER TR, PACK GT. The familial aspect of malignant melanoma. Arch Dermatol. 1962 Jul;86:35-9. doi: 10.1001/archderm.1962.01590070041005. PMID: 14474110.
Copy Download .nbib Format: NLM
Precision medicine driven by cancer systems biology.

Cancer metastasis reviews

Filipp FV.
PMID: 28265786
Cancer Metastasis Rev. 2017 Mar;36(1):91-108. doi: 10.1007/s10555-017-9662-4.

Molecular insights from genome and systems biology are influencing how cancer is diagnosed and treated. We critically evaluate big data challenges in precision medicine. The melanoma research community has identified distinct subtypes involving chronic sun-induced damage and the mitogen-activated...

Cite
Filipp FV. Precision medicine driven by cancer systems biology. Cancer Metastasis Rev. 2017;36(1):91-108doi: 10.1007/s10555-017-9662-4.
Filipp, F. V. (2017). Precision medicine driven by cancer systems biology. Cancer metastasis reviews, 36(1), 91-108. https://doi.org/10.1007/s10555-017-9662-4
Filipp, Fabian V. "Precision medicine driven by cancer systems biology." Cancer metastasis reviews vol. 36,1 (2017): 91-108. doi: https://doi.org/10.1007/s10555-017-9662-4
Filipp FV. Precision medicine driven by cancer systems biology. Cancer Metastasis Rev. 2017 Mar;36(1):91-108. doi: 10.1007/s10555-017-9662-4. PMID: 28265786; PMCID: PMC5385204.
Copy Download .nbib Format: NLM
New pieces of the melanoma puzzle uncovered.

Annals of oncology : official journal of the European Society for Medical Oncology

Troiani T, Napolitano S.
PMID: 32949715
Ann Oncol. 2020 Nov;31(11):1430-1431. doi: 10.1016/j.annonc.2020.09.005. Epub 2020 Sep 16.

No abstract available.

Cite
Troiani T, Napolitano S. New pieces of the melanoma puzzle uncovered. Ann Oncol. 2020;31(11):1430-1431doi: 10.1016/j.annonc.2020.09.005.
Troiani, T., & Napolitano, S. (2020). New pieces of the melanoma puzzle uncovered. Annals of oncology : official journal of the European Society for Medical Oncology, 31(11), 1430-1431. https://doi.org/10.1016/j.annonc.2020.09.005
Troiani, T, and Napolitano, S. "New pieces of the melanoma puzzle uncovered." Annals of oncology : official journal of the European Society for Medical Oncology vol. 31,11 (2020): 1430-1431. doi: https://doi.org/10.1016/j.annonc.2020.09.005
Troiani T, Napolitano S. New pieces of the melanoma puzzle uncovered. Ann Oncol. 2020 Nov;31(11):1430-1431. doi: 10.1016/j.annonc.2020.09.005. Epub 2020 Sep 16. PMID: 32949715.
Copy Download .nbib Format: NLM
Using Genomic Sequencing to Improve Management in Melanoma.

Oncology (Williston Park, N.Y.)

Funchain P, Tarhini AA.
PMID: 29548064
Oncology (Williston Park). 2018 Mar 15;32(3):98-101, 104.

Rapidly advancing genomic sequencing technologies are changing all areas of cancer, from diagnosis to surveillance, and prognostication to treatment. The role of genomic testing in melanoma is expanding, and multiple genomically based tests are available, including somatic tumor sequencing...

Cite
Funchain P, Tarhini AA. Using Genomic Sequencing to Improve Management in Melanoma. Oncology (Williston Park). 2018;32(3):98-101, 104
Funchain, P., & Tarhini, A. A. (2018). Using Genomic Sequencing to Improve Management in Melanoma. Oncology (Williston Park, N.Y.), 32(3), 98-101, 104.
Funchain, Pauline, and Tarhini, Ahmad A. "Using Genomic Sequencing to Improve Management in Melanoma." Oncology (Williston Park, N.Y.) vol. 32,3 (2018): 98-101, 104.
Funchain P, Tarhini AA. Using Genomic Sequencing to Improve Management in Melanoma. Oncology (Williston Park). 2018 Mar 15;32(3):98-101, 104. PMID: 29548064.
Copy Download .nbib Format: NLM
Advances in drug development. BRAF validation in melanoma.

Clinical advances in hematology & oncology : H&O

Flaherty K.
PMID: 20351680
Clin Adv Hematol Oncol. 2010 Jan;8(1):31-4.

No abstract available.

Cite
Flaherty K. Advances in drug development. BRAF validation in melanoma. Clin Adv Hematol Oncol. 2010;8(1):31-4
Flaherty, K. (2010). Advances in drug development. BRAF validation in melanoma. Clinical advances in hematology & oncology : H&O, 8(1), 31-4.
Flaherty, Keith. "Advances in drug development. BRAF validation in melanoma." Clinical advances in hematology & oncology : H&O vol. 8,1 (2010): 31-4.
Flaherty K. Advances in drug development. BRAF validation in melanoma. Clin Adv Hematol Oncol. 2010 Jan;8(1):31-4. PMID: 20351680.
Copy Download .nbib Format: NLM
Boris Bastian.

Pigment cell & melanoma research

Herlyn M.
PMID: 20973934
Pigment Cell Melanoma Res. 2010 Dec;23(6):834. doi: 10.1111/j.1755-148X.2010.00724.x.

No abstract available.

Cite
Herlyn M. Boris Bastian. Pigment Cell Melanoma Res. 2010;23(6):834doi: 10.1111/j.1755-148X.2010.00724.x.
Herlyn, M. (2010). Boris Bastian. Pigment cell & melanoma research, 23(6), 834. https://doi.org/10.1111/j.1755-148X.2010.00724.x
Herlyn, Meenhard. "Boris Bastian." Pigment cell & melanoma research vol. 23,6 (2010): 834. doi: https://doi.org/10.1111/j.1755-148X.2010.00724.x
Herlyn M. Boris Bastian. Pigment Cell Melanoma Res. 2010 Dec;23(6):834. doi: 10.1111/j.1755-148X.2010.00724.x. PMID: 20973934.
Copy Download .nbib Format: NLM
[Molecular diagnostics and personalized medicine in malignant melanoma].

Zhonghua bing li xue za zhi = Chinese journal of pathology

Cheng L, Zhao D, Liu L, Wang X.
PMID: 25471513
Zhonghua Bing Li Xue Za Zhi. 2014 Sep;43(9):639-43.

No abstract available.

Cite
Cheng L, Zhao D, Liu L, et al. [Molecular diagnostics and personalized medicine in malignant melanoma]. Zhonghua Bing Li Xue Za Zhi. 2014;43(9):639-43
Cheng, L., Zhao, D., Liu, L., & Wang, X. (2014). [Molecular diagnostics and personalized medicine in malignant melanoma]. Zhonghua bing li xue za zhi = Chinese journal of pathology, 43(9), 639-43.
Cheng, Liang, et al. "[Molecular diagnostics and personalized medicine in malignant melanoma]." Zhonghua bing li xue za zhi = Chinese journal of pathology vol. 43,9 (2014): 639-43.
Cheng L, Zhao D, Liu L, Wang X. [Molecular diagnostics and personalized medicine in malignant melanoma]. Zhonghua Bing Li Xue Za Zhi. 2014 Sep;43(9):639-43. Chinese. PMID: 25471513.
Copy Download .nbib Format: NLM
MiRNA in melanoma-derived exosomes.

Cancer letters

Gajos-Michniewicz A, Duechler M, Czyz M.
PMID: 24513178
Cancer Lett. 2014 May 28;347(1):29-37. doi: 10.1016/j.canlet.2014.02.004. Epub 2014 Feb 07.

Proteins, RNAs and viruses can be spread through exosomes, therefore transport utilizing these nanovesicles is of the great interest. MiRNAs are common exosomal constituents capable of influencing expression of a variety of target genes. MiRNA signatures of exosomes are...

Cite
Gajos-Michniewicz A, Duechler M, Czyz M. MiRNA in melanoma-derived exosomes. Cancer Lett. 2014;347(1):29-37doi: 10.1016/j.canlet.2014.02.004.
Gajos-Michniewicz, A., Duechler, M., & Czyz, M. (2014). MiRNA in melanoma-derived exosomes. Cancer letters, 347(1), 29-37. https://doi.org/10.1016/j.canlet.2014.02.004
Gajos-Michniewicz, Anna, et al. "MiRNA in melanoma-derived exosomes." Cancer letters vol. 347,1 (2014): 29-37. doi: https://doi.org/10.1016/j.canlet.2014.02.004
Gajos-Michniewicz A, Duechler M, Czyz M. MiRNA in melanoma-derived exosomes. Cancer Lett. 2014 May 28;347(1):29-37. doi: 10.1016/j.canlet.2014.02.004. Epub 2014 Feb 07. PMID: 24513178.
Copy Download .nbib Format: NLM
Rare victory in fight against melanoma.

Nature

Ledford H.
PMID: 20829766
Nature. 2010 Sep 09;467(7312):140-1. doi: 10.1038/467140b.

No abstract available.

Cite
Ledford H. Rare victory in fight against melanoma. Nature. 2010;467(7312):140-1doi: 10.1038/467140b.
Ledford, H. (2010). Rare victory in fight against melanoma. Nature, 467(7312), 140-1. https://doi.org/10.1038/467140b
Ledford, Heidi. "Rare victory in fight against melanoma." Nature vol. 467,7312 (2010): 140-1. doi: https://doi.org/10.1038/467140b
Ledford H. Rare victory in fight against melanoma. Nature. 2010 Sep 09;467(7312):140-1. doi: 10.1038/467140b. PMID: 20829766.
Copy Download .nbib Format: NLM
Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response.

Clinical cancer research : an official journal of the American Association for Cancer Research

Patel SP, Othus M, Chae YK, Kurzrock R.
PMID: 32414761
Clin Cancer Res. 2020 May 15;26(10):2434. doi: 10.1158/1078-0432.CCR-20-0790.

No abstract available.

Cite
Patel SP, Othus M, Chae YK, et al. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clin Cancer Res. 2020;26(10):2434doi: 10.1158/1078-0432.CCR-20-0790.
Patel, S. P., Othus, M., Chae, Y. K., Kurzrock, R. (2020). Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(10), 2434. https://doi.org/10.1158/1078-0432.CCR-20-0790
Patel, Sandip P, et al. "Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,10 (2020): 2434. doi: https://doi.org/10.1158/1078-0432.CCR-20-0790
Patel SP, Othus M, Chae YK, Kurzrock R. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clin Cancer Res. 2020 May 15;26(10):2434. doi: 10.1158/1078-0432.CCR-20-0790. PMID: 32414761.
Copy Download .nbib Format: NLM
ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?.

Annals of surgical oncology

Kangas-Dick A, Berger AC, Koshenkov V.
PMID: 33479864
Ann Surg Oncol. 2021 Aug;28(8):4590-4591. doi: 10.1245/s10434-021-09599-3. Epub 2021 Jan 21.

No abstract available.

Cite
Kangas-Dick A, Berger AC, Koshenkov V. ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?. Ann Surg Oncol. 2021;28(8):4590-4591doi: 10.1245/s10434-021-09599-3.
Kangas-Dick, A., Berger, A. C., & Koshenkov, V. (2021). ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?. Annals of surgical oncology, 28(8), 4590-4591. https://doi.org/10.1245/s10434-021-09599-3
Kangas-Dick, Aaron, et al. "ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?." Annals of surgical oncology vol. 28,8 (2021): 4590-4591. doi: https://doi.org/10.1245/s10434-021-09599-3
Kangas-Dick A, Berger AC, Koshenkov V. ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?. Ann Surg Oncol. 2021 Aug;28(8):4590-4591. doi: 10.1245/s10434-021-09599-3. Epub 2021 Jan 21. PMID: 33479864.
Copy Download .nbib Format: NLM
cDNA array technology in melanoma: an overview.

Journal of cellular physiology

Baldi A, Santini D, De Luca A, Paggi MG.
PMID: 12811814
J Cell Physiol. 2003 Aug;196(2):219-23. doi: 10.1002/jcp.10255.

Genetic aberrations, mostly resulting in changes in gene expression, are critical events in cancer onset and progression. The advent of the cDNA array technology allows the screening and the efficient measurement of expression of thousands genes simultaneously in a...

Cite
Baldi A, Santini D, De Luca A, et al. cDNA array technology in melanoma: an overview. J Cell Physiol. 2003;196(2):219-23doi: 10.1002/jcp.10255.
Baldi, A., Santini, D., De Luca, A., & Paggi, M. G. (2003). cDNA array technology in melanoma: an overview. Journal of cellular physiology, 196(2), 219-23. https://doi.org/10.1002/jcp.10255
Baldi, Alfonso, et al. "cDNA array technology in melanoma: an overview." Journal of cellular physiology vol. 196,2 (2003): 219-23. doi: https://doi.org/10.1002/jcp.10255
Baldi A, Santini D, De Luca A, Paggi MG. cDNA array technology in melanoma: an overview. J Cell Physiol. 2003 Aug;196(2):219-23. doi: 10.1002/jcp.10255. PMID: 12811814.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 20 entries